健帆生物(300529) - 2017 Q3 - 季度财报

Financial Performance - Revenue for the reporting period reached CNY 163,323,027.44, a year-on-year increase of 43.77%[7] - Net profit attributable to shareholders was CNY 54,444,109.21, reflecting a growth of 40.59% compared to the same period last year[7] - The net profit after deducting non-recurring gains and losses was CNY 49,583,838.27, up 32.16% year-on-year[7] - The basic earnings per share increased by 30.00% to CNY 0.13[7] - Net profit for the first nine months of 2017 rose by 46.11% to ¥203,443,582.93 from ¥139,235,847.36 in 2016, attributed to enhanced market expansion efforts[21] - Net profit for the period was CNY 54,432,148.76, up from CNY 38,726,797.51, indicating a growth of approximately 40.5%[39] - Net profit for the period was ¥203,443,582.93, representing a 46.2% increase compared to ¥139,235,847.36 in the previous period[46] Assets and Liabilities - Total assets increased by 21.24% to CNY 1,575,977,480.18 compared to the end of the previous year[7] - The company reported a net asset attributable to shareholders of CNY 1,308,111,622.78, up 10.48% from the previous year[7] - Total current assets increased to ¥1,164,999,594.59 from ¥999,201,238.74, with cash and cash equivalents significantly reduced[29] - Total liabilities rose to ¥267,468,796.97 from ¥115,811,528.65, indicating a substantial increase in financial obligations[31] - Total liabilities rose to CNY 269,006,561.13, compared to CNY 115,402,897.93 in the previous period, indicating a significant increase[35] - The company's equity totaled CNY 1,309,031,619.00, up from CNY 1,185,046,942.99, reflecting a growth of approximately 10.5%[35] Cash Flow - Cash flow from operating activities for the year-to-date reached CNY 207,020,420.79, an increase of 122.76%[7] - The cash inflow from operating activities amounted to CNY 611,156,878.38, an increase of 37.2% compared to CNY 445,658,875.62 in the previous period[53] - The net cash flow from operating activities was CNY 207,020,420.79, significantly up from CNY 92,934,425.69 in the same period last year, representing a growth of 122.2%[53] - The total cash inflow from investment activities was CNY 1,512,641,041.11, compared to CNY 120,000.00 in the previous period[54] - The cash outflow from investment activities reached CNY 2,308,442,665.28, up from CNY 223,035,564.59, resulting in a net cash flow from investment activities of -CNY 795,801,624.17[54] - The cash inflow from financing activities was CNY 138,856,640.00, a decrease from CNY 429,600,000.00 in the previous period[56] - The net cash flow from financing activities was CNY 61,952,420.16, down from CNY 422,107,502.30 in the previous period[56] - The ending cash and cash equivalents balance was CNY 233,254,833.64, a decrease from CNY 579,453,522.66 at the end of the previous period[54] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,700[11] - The top shareholder, Dong Fan, holds 47.61% of the shares, totaling 198,339,613 shares, with 47,100,000 shares pledged[11] Other Financial Metrics - The weighted average return on equity was 4.25%, a decrease of 0.23% compared to the previous year[7] - The company reported a significant increase in other receivables by 609.49% to ¥2,557,736.89, primarily due to an increase in employee advances[19] - The goodwill increased by 142.28% to ¥16,985,722.70, resulting from the acquisition of Tianjin Standard Biological Preparations Co., Ltd.[19] - The company’s financial expenses decreased by 74.88% to -¥5,761,281.83, reflecting increased interest income from higher cash balances[20] - The company’s other income increased by 137.66% to ¥14,390,591.79, primarily due to an increase in government subsidies received[21] - The company’s long-term prepaid expenses rose by 69.54% to ¥1,446,288.07, mainly due to increased renovation costs[19] - The company’s capital reserve increased by 36.50% to ¥513,252,437.77, driven by the implementation of a restricted stock incentive plan[19] - Cash dividends distributed amounted to ¥76,364,939.84, with no dividends distributed in the previous period[23] - Sales expenses for the period were CNY 50,106,476.46, compared to CNY 33,345,373.18 in the previous year, indicating increased investment in sales[38] - The company reported an investment income of CNY 2,594,520.54 during the period[38] - Deferred income decreased to CNY 28,599,607.81 from CNY 31,525,124.61, indicating a reduction in future obligations[35] - The company achieved a profit before tax of ¥243,424,991.98, up from ¥166,233,503.31 in the previous period, indicating a growth of 46.4%[46] Inventory and Operating Costs - Operating costs amounted to CNY 100,580,900.95, compared to CNY 68,813,343.23 in the same period last year, reflecting a significant rise[38] - Total operating costs amounted to ¥275,715,550.89, up 29.3% from ¥213,133,366.15 in the previous period[44] - Inventory decreased slightly to ¥46,812,841.12 from ¥50,483,745.08, indicating a potential reduction in stock levels[29] - Sales expenses increased to ¥133,179,365.23, up from ¥103,394,177.29 in the previous period, reflecting a 28.9% rise[44] - Management expenses rose to ¥59,229,901.44, compared to ¥46,145,345.21 in the previous period, marking a 28.4% increase[44] Audit Status - The company has not undergone an audit for the third quarter report[57]